Table II.
Genotype distribution in women with lung cancer and controls, by race
| Genotype | Total sample |
White |
Black |
||||||
| Cases N = 504, n (%) | Controls N = 527, n (%) | P-value | Cases N = 389, n (%) | Controls N = 406, n (%) | P-value | Cases N = 115, n (%) | Controls N = 121, n (%) | P-value | |
| CYP1A1 Msp1 | |||||||||
| T/T | 373 (75.2) | 402 (77.4) | 0.23 | 308 (80.0) | 320 (80.0) | 0.60 | 65 (58.6) | 82 (68.9) | 0.16 |
| C/T | 109 (22.0) | 110 (21.2) | 70 (18.2) | 76 (19.0) | 39 (35.1) | 34 (28.6) | |||
| C/C | 14 (2.8) | 7 (1.4) | 7 (1.8) | 4 (1.0) | 7 (6.3) | 3 (2.5) | |||
| CYP1A1 Ile462Vala | |||||||||
| A/A | 464 (92.4) | 489 (93.5) | 0.25 | 359 (92.8) | 372 (92.5) | 0.38 | 105 (91.3) | 117 (96.7) | 0.08 |
| A/G | 38 (7.6) | 32 (6.1) | 28 (7.2) | 28 (7.0) | 10 (8.7) | 4 (3.3) | |||
| G/G | 0 (0) | 2 (0.4) | 0 (0) | 2 (0.5) | 0 (0) | 0 (0) | |||
| CYP1B1b | |||||||||
| C/C | 120 (24.0) | 144 (27.4) | 0.45 | 119 (30.9) | 136 (33.6) | 0.70 | 1 (0.9) | 8 (6.6) | 0.07 |
| C/G | 234 (46.9) | 240 (45.6) | 190 (49.4) | 195 (48.1) | 44 (38.6) | 45 (37.2) | |||
| G/G | 145 (29.1) | 142 (27.0) | 76 (19.7) | 74 (18.3) | 69 (60.5) | 68 (56.2) | |||
| CYP17c | |||||||||
| A1/A1 | 180 (35.9) | 209 (39.7) | 0.34 | 136 (35.1) | 159 (39.2) | 0.36 | 44 (38.6) | 50 (41.3) | 0.01 |
| A1/A2 | 246 (49.0) | 251 (47.6) | 200 (51.5) | 189 (46.5) | 46 (40.4) | 62 (51.2) | |||
| A2/A2 | 76 (15.1) | 67 (12.7) | 52 (13.4) | 58 (14.3) | 24 (21.0) | 9 (7.4) | |||
| CYP19A1d | |||||||||
| <10 | 222 (44.8) | 217 (43.2) | 0.61 | 137 (35.8) | 133 (34.6) | 0.74 | 85 (75.9) | 84 (71.2) | 0.42 |
| 10+ | 273 (55.2) | 285 (56.8) | 246 (64.2) | 251 (65.4) | 27 (24.1) | 34 (28.8) | |||
| NQO1 | |||||||||
| C/C | 348 (69.6) | 350 (66.5) | 0.40 | 271 (70.0) | 271 (66.9) | 0.32 | 77 (67.5) | 79 (65.3) | 0.82 |
| C/T | 129 (25.8) | 155 (29.5) | 97 (25.1) | 119 (29.4) | 32 (28.0) | 36 (29.8) | |||
| T/T | 23 (4.6) | 21 (4.0) | 19 (4.9) | 15 (3.7) | 4 (3.5) | 6 (4.9) | |||
| GSTM1 | |||||||||
| 0 (+) | 256 (51.0) | 299 (57.1) | 0.05 | 178 (45.9) | 206 (51.1) | 0.14 | 78 (68.4) | 93 (76.9) | 0.15 |
| 1 (null) | 246 (49.0) | 225 (42.9) | 210 (54.1) | 197 (48.9) | 36 (31.6) | 28 (23.1) | |||
| GSTT1 | |||||||||
| 0 (+) | 398 (79.3) | 419 (79.5) | 0.88 | 311 (80.1) | 324 (79.8) | 0.90 | 87 (75.7) | 95 (78.5) | 0.60 |
| 1 (null) | 105 (20.7) | 108 (20.5) | 77 (19.9) | 82 (20.2) | 28 (24.3) | 26 (21.5) | |||
| GSTP1 | |||||||||
| G/G | 63 (12.6) | 84 (16.1) | 0.30 | 38 (9.8) | 56 (13.8) | 0.21 | 25 (21.9) | 28 (23.3) | 0.86 |
| A/G | 238 (47.6) | 244 (46.3) | 177 (45.9) | 184 (45.3) | 61 (53.5) | 60 (50.0) | |||
| A/A | 199 (39.8) | 198 (37.6) | 171 (44.3) | 166 (40.9) | 28 (24.6) | 32 (26.7) | |||
| COMTe | |||||||||
| G/G | 134 (27.0) | 151 (28.9) | 0.47 | 78 (20.3) | 92 (22.8) | 0.46 | 56 (50.0) | 59 (49.2) | 0.79 |
| A/G | 251 (50.5) | 244 (46.6) | 205 (53.2) | 197 (48.9) | 46 (41.1) | 47 (39.2) | |||
| A/A | 112 (22.5) | 128 (24.5) | 102 (26.5) | 114 (28.3) | 10 (8.9) | 14 (11.7) | |||
| XRCC1f | |||||||||
| G/G | 258 (51.4) | 248 (47.1) | 0.05 | 172 (44.4) | 160 (39.4) | 0.06 | 86 (74.8) | 88 (72.7) | 0.80 |
| A/G | 182 (36.2) | 228 (43.2) | 159 (41.1) | 200 (49.3) | 23 (20.0) | 28 (23.2) | |||
| A/A | 62 (12.4) | 51 (9.7) | 56 (14.5) | 46 (11.3) | 6 (5.2) | 5 (4.1) | |||
CYP1A1 primers: 5′-GGCAAGCGGAAGTGTATCG-3′ and 5′-CAGGATAGCCAGGAAGAGAAAGAC-3′. CYP1A1 probe sequences: 5′-VIC-TGAGACCATTGCCCGC-MGB-3′ and 5′-FAM-AGACCGTTGCCCGC-MGB-3′.
CYP1B1 primers: 5′-CACTGCCAACACCTCTGTCTTG-3′ and 5′-AAGAATCGAGCTGGATCAAAGTTC-3′. CYP1B1 probe sequences: 5′-6FAM-ATGACCCACTGAAGTG-MGBNFQ-3′ and 5′-VIC-ATGACCCAGTGAAGTG-MGBNFQ-3′.
CYP17 primers: 5′-CACGAGCTCCCACATGGT-3′ and 5′-CCTCCTTGTGCCCTAGAGTTG-3′. CYP17 probe sequences: 5′-VIC-ATAGACAGCAGTGGAGTAG-MGB-3′ and 5′-FAM-ACAGCGGTGGAGTAG-MGB-3′.
Individuals are recorded as ‘10+’ if they have at least one set of repeats that is ≥10 repeats in length and <10 if both sets of repeats are <10 repeats.
COMT primers: 5′-CGACTGTGCCGCCATCA-3′ and 5′-AACGGGTCAGGCATGCA-3′. COMT probe sequences: 5′-FAM-CTTGTCCTTCACGCCAGCGAAAT-TAMRA-3′ and 5′-VIC-CCTTGTCCTTCATGCCAGCGAA-TAMRA-3′.
XRCC1 primers: 5′-GTGGGTGCTGGACTGTCA-3′ and 5′-AACGGGTCAGGCATGCA-3′. XRCC1 probe sequences: 5′-VIC-CCCTCCCAGAGGTAA-MGB-3′ and 5′-FAM-CCTCCCGGAGGTAA-MGB-3′.